Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Pulmonary Arterial Hypertension, Healthy
Phase Not Applicable
Enrollment 6
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand \[11C\]PBR28) in the lungs of patients living with PAH relative to age matched controls. If so, TSPO PET may be a useful technique to non-invasively monitor response to therapy. To do this, we will perform 2 \[11C\]PBR28 PET scans. The first will quantify the total \[11C\]PBR28 PET signal. This signal is a combination of the specific signal (VS) and the nonspecific signal (VND). The second scan will be performed following dosing with an unlabelled TSPO ligand. By directly measuring the total \[11C\]PBR28 signal (scan 1) and the nonspecific \[11C\]PBR28 signal (scan 2) we can therefore calculate the specific \[11C\]PBR28 signal, and hence the amount of TSPO in the lung.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Radiation: TSPO PET scan (11C-PBR28) — PET scan

Primary Outcomes

  • The specific and non-specific fractions of the [11C]PBR28 signal in the lungs of healthy individuals and PAH patients. (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-02-01
Completion: 2025-04
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 6 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Imperial College London
Principal Investigators:
  • Martin Wilkins (PRINCIPAL_INVESTIGATOR) - Imperial College London
Contact Information
Study Contact:
David Owen, MD PhD
07801140800
d.owen@imperial.ac.uk
Imperial Clinical Research Facility
Interventions
  • Radiation: TSPO PET scan (11C-PBR28) — PET scan
Study Locations (1 sites)
Imperial Clinical Research Facility, London, NW3 2LE United Kingdom
Eligibility Criteria
Inclusion Criteria: Able to provide written informed consent prior to any study mandated procedures. Able to lie comfortably on back for up to 90 minutes at a time. Fertile females (women of childbearing potential) are eligible to participate after a negative highly sensitive pregnancy test, if they are taking a highly effective method of contraception other than the oral contraceptive pill until the end of relevant systemic exposure. Male participants who are fertile are eligible to participate if they are willing to comply with the contraceptive requirements Exclusion Criteria: Unable to provide informed consent and/or are non-fluent speakers of the English language TT Genotype at the rs6971 locus Clinically-significant renal disease (confirmed by creatinine clearance \<30 ml/min per 1.73m2) Clinically-significant liver disease (confirmed by serum transaminases \>2 times than upper normal limit) Anaemia confirmed by haemoglobin concentration \<10 g/dl Sickle cell disease or thalassaemia History of uncontrolled systemic hypertension Acute infection (including eye, dental, and skin infections) Chronic inflammatory disease including HIV, and Hepatitis B Women of childbearing potential who are pregnant or breastfeeding Patients who have received an Investigational Medicinal Product (IMP) within 5 half-lives of the last dose of the IMP or 1 month (which ever is greater) before the baseline visit Participation in a research study involving significant ionisation radiation within the last 3 years Significant radiation exposure other than dental X-rays in last 1 year Positive Allen's test. \-
Conditions Locally Advanced or Metastatic Breast Ca...
Phase PHASE2, PHASE3
Enrollment 374
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: SPH4336 Tablets 400mg — SPH4336 Tablets :Orally, 400mg once a day; 28 days/cycle Letrozole tablets :Orally, 2.5mg once a day; 28 days/cycle
  • Drug: SPH4336 Tablets Placebo — SPH4336 Tablets Placebo:Orally,28 days/cycle Letrozole tablets :Orally, 2.5mg once a day; 28 days/cycle

Primary Outcomes

  • response rate (ORR) (Approximately 3years)
  • Progression-free survival (PFS) (Approximately 3years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2023-04-24
Completion: 2026-05-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 374 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
Contact Information
Study Contact:
Shusen Wang
0086-020-87343811
wangshs@sysucc.org.cn
Jian Liu
0086-0591-62752181
fjszlyyjgb@163.com
Fujian Cancer Hospital
Shusen Wang
0086-020-87343811
wangshs@sysucc.org.cn
Affiliated Cancer Hospital, Sun Yat-sen University
Interventions
  • Drug: SPH4336 Tablets 400mg — SPH4336 Tablets :Orally, 400mg once a day; 28 days/cycle Letrozole tablets :Orally, 2.5mg once a day; 28 days/cycle
  • Drug: SPH4336 Tablets Placebo — SPH4336 Tablets Placebo:Orally,28 days/cycle Letrozole tablets :Orally, 2.5mg once a day; 28 days/cycle
Study Locations (9 sites)
Fujian Cancer Hospital, Fuzhou, Fujian 350014 China
Affiliated Cancer Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510060 China
The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou 550000 China
AnYang Tumor Hospital, Anyang, Henan 455001 China
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 450052 China
Pingxiang People's Hospital, Pingxiang, Jiangxi 337099 China
The Second Norman Bethune Hospital of Jilin Univer, Changchun, Jilin 130022 China
General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750003 China
Peking University Cancer Hospital, Beijing, 100142 China
Eligibility Criteria
Inclusion Criteria: 1. Patients who voluntarily participate in the study, completely understand the study, and voluntarily sign the informed consent form (ICF). 2. Female, ≥ 18 and ≤ 75 years of age at the time of signing the ICF. 3. ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1. 4. Life expectancy ≥ 3 months. 5. Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies, with hormone receptor positive and human epidermal growth factor receptor 2 negative confirmed by tumor histopathology and molecular pathology. 6. No previous systemetic therapy for locally advanced or metastatic diseases that cannot receive radical surgeries/other local therapies. 7. At least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors. 8. Postmenopausal or premenopausal/perimenopausal female patients. Premenopausal or perimenopausal women should consent to receive goserelin therapy during the study. 9. Laboratory test results before randomization meet the relevant requirements for organ function. Exclusion Criteria: 1. Prior treatment with any CDK4/6 (Cyclin dependent kinase)inhibitor. 2. Inflammatory breast cancer. 3. Patients unsuitable for endocrine therapy at the investigator's discretion. 4. History of other malignancies within 5 years prior to the start of study treatment. 5. Patients with known central nervous system metastases. 6. Taking anti-tumor traditional Chinese medicines at the time of signing the ICF. 7. Having undergone a surgery within 28 days prior to the start of study treatment, and hasn't yet recovered from adverse reactions of the surgery. 8. History of myocardial infarction, unstable angina pectoris, severe arrhythmia, and symptomatic congestive heart failure before the start of study treatment; NYHA( New York Heart Association) Class ≥II; QTcF≥ 470 ms; LVEF(Left Ventricular Ejection Fractions)≤ 50%. 9. History of ischemic stroke or severe thromboembolic disease before the start of study treatment. 10. Being receiving potent CYP3A4 inhibitors or inducers at the time of signing the ICF. 11. Hepatitis B surface antigen positive and HBV(Hepatitis B Virus) DNA \> 2,000 IU/mL or 104 copies/mL; HCV(hepatitis C virus) antibody positive and HCV RNA positive; or known HIV infection. 12. Patients who participated in a clinical trial and received other investigational drugs within 30 days before the start of study treatment. 13. History of severe anaphylactic diseases, history of severe drug allergy, or known allergy to any ingredient of the investigational product. 14. Presence of diseases or conditions that may impact drug administration or gastrointestinal absorption before the start of study treatment, in the opinion of the investigator, makes them an unsuitable candidate for the study. 15. Uncontrolled infections within 2 weeks before the start of study treatment, in the opinion of the investigator, makes them an unsuitable candidate for the study. 16. Pregnant or lactating women. 17. Known history of substance abuse, excessive drinking, or illegal drug addiction; history of confirmed neurological or mental disorders. 18. Presence of other diseases judged by the investigator that the risks of receiving the study treatment outweigh its benefits, or any other reason for which patients are ineligible for the study as assessed by the investigator and the sponsor.
Conditions Metastatic Breast Cancer
Phase PHASE2
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Estradiol — Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer

Primary Outcomes

  • Clinical Benefit Rate (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-05-04
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dartmouth-Hitchcock Medical Center
Principal Investigators:
  • Muhammad Azfal, MD (PRINCIPAL_INVESTIGATOR) - Dartmouth-Hitchcock Medical Center
Contact Information
Study Contact:
Research Nurse
1-800-639-6918
Cancer.Research.Nurse@dartmouth.edu
Interventions
  • Drug: Estradiol — Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
Study Locations (1 sites)
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756 United States
Eligibility Criteria
Inclusion Criteria: * Post-menopausal women with ER+ breast cancer. * Metastatic or locoregional recurrence not amenable to treatment with curative * intent. * Received ≥1 prior line of endocrine-based therapy (e.g., including tamoxifen, aromatase inhibitors, fulvestrant, or combinations) in the advanced/metastatic setting Exclusion Criteria: * During the study Treatment Phase with 17b-estradiol, no concurrent anti-cancer therapies are allowed with the following exceptions: * Exception: Trastuzumab is allowed for the treatment of subjects with a history of HER2+ disease, and will be used at the physician's discretion. * Exception: Anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) are permitted. * Any investigational cancer therapy in the last 3 weeks. * Known CNS disease, unless clinically stable for ≥ 3 months. * History of any of the following: * Deep venous thrombosis. * Pulmonary embolism. * Stroke. * Acute myocardial infarction. * Congestive heart failure. * Previous malignancy not treated with curative intent, or with an estimated recurrence risk ≥30%.
Conditions Sentinel Lymph Node, Breast Cancer, Loca...
Phase Not Applicable
Enrollment 162
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Target Axillary Dissection — TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection

Primary Outcomes

  • TAD validation in locally advanced breast cancer (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-02-01
Completion: 2027-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 162 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Universitari de Bellvitge
Principal Investigators:
  • amparo Garcia-Tejedor, MDPhD (PRINCIPAL_INVESTIGATOR) - Instituto de Investigación Biomédica de Bellvitge (IDIBELL)
Contact Information
Study Contact:
Amparo García-Tejedor, MDPhD
0034-932607702
agarciat@bellvitgehospital.cat
Amparo Garcia-Tejedor, MDPhD
0034-660223417
agarciat@bellvitgehospital.cat
Hospital de Bellvitge
Isaac Cebrecos, MD
CEBRECOS@clinic.cat
Hospital Clínico y Provincial de Barcelona
Interventions
  • Procedure: Target Axillary Dissection — TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection
Study Locations (2 sites)
Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona 08907 Spain
Hospital Clínico y Provincial de Barcelona, Barcelona, 08036 Spain
Eligibility Criteria
Inclusion Criteria: * Axillary lymph node metastasis proven by cytology * Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis) * Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria * Neoadjuvant chemotherapy Exclusion Criteria: * cN3 verified by imaging tests * N2 due to internal mammary involvement (N2b). * Tumors whose surrogate molecular subtype is luminal A. * Patients undergoing neoadjuvant endocrine therapy * Patients with local recurrences and metastatic tumors.
Conditions Early-stage Breast Cancer, HER2-positive...
Phase PHASE3
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Neratinib is an irreversible pan-HER tyrosine kinase inhibitor (TKI). Currently, no studies have investigated the use of macromolecular anti-HER2 agents combined with TKIs for the treatment of non-pCR HER2-positive breast cancer following neoadjuvant therapy. Furthermore, there are no prospective randomized controlled trials comparing trastuzumab plus pertuzumab versus trastuzumab plus TKIs in HER2-positive breast cancer patients with residual cancer burden class (RCB) I or II after neoadjuvant trastuzumab and pertuzumab. Therefore, this study aimed to evaluate the efficacy and safety of adjuvant trastuzumab plus neratinib in patients with hormone receptor-positive/HER2-positive breast cancer and RCB 0/I following neoadjuvant trastuzumab and pertuzumab therapy.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab and neratinib — Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and neratinib 240 mg orally once daily. The trastuzumab treatment will be continued for a total of 18 cycles, encompassing both the preoperative and adjuvant phases, while neratinib will be maintained throughout the adjuvant period.
  • Drug: Trastuzumab and Pertuzumab — Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and pertuzumab (840 mg IV loading dose, followed by 420 mg IV once every 3 weeks). This regimen will be repeated for a total of 18 cycles,encompassing both the preoperative and adjuvant phases.

Primary Outcomes

  • Invasive disease free survival, IDFS (During the 3 years after random assignment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-03-14
Completion: 2028-11-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Chang Gong
13925089353
gchang@mail.sysu.edu.cn
chang Gong
13925089353
gchang@mail.sysu.edu.cn
Sun Yat-sen University Sun Yat-sen Memorial Hospital
Interventions
  • Drug: Trastuzumab and neratinib — Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and neratinib 240 mg orally once daily. The trastuzumab treatment will be continued for a total of 18 cycles, encompassing both the preoperative and adjuvant phases, while neratinib will be maintained throughout the adjuvant period.
  • Drug: Trastuzumab and Pertuzumab — Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and pertuzumab (840 mg IV loading dose, followed by 420 mg IV once every 3 weeks). This regimen will be repeated for a total of 18 cycles,encompassing both the preoperative and adjuvant phases.
Study Locations (1 sites)
Sun Yat-sen University Sun Yat-sen Memorial Hospital, Guangzhou, China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18-70 years; 2. Eastern Cooperative Oncology Group performance status of 0 or 1; 3. Clinical stage at initial diagnosis (per the 8th edition of the American Joint Committee on Cancer Staging Manual): cT1-4/N1-3/M0 (cT1mi/N0 or cT1a-b/N0 are eligible), meeting the criteria for neoadjuvant therapy as per NCCN 2022 guidelines; 4. Histologically confirmed hormone receptor-positive (estrogen receptor ≥1% and/or progesterone receptor ≥1%) and HER2-positive (immunohistochemistry 3+ or fluorescence in situ hybridization-positive) invasive breast cancer; 5. Completion of ≥4 cycles of neoadjuvant therapy with trastuzumab and pertuzumab, without recurrence or metastatic disease prior to adjuvant treatment; residual cancer burden class 0 or I after neoadjuvant therapy; time from initial surgery to randomization ≤12 weeks; 6. Adequate organ function within 2 weeks prior to screening (without transfusion or use of growth factors): * Absolute neutrophil count ≥1.5 × 10⁹/L; * Platelet count ≥90 × 10⁹/L; * Hemoglobin ≥90 g/L; * Total bilirubin ≤1.5 × upper limit of normal (ULN); * Alanine aminotransferase and aspartate aminotransferase ≤1.5 × ULN; 7. Post-neoadjuvant therapy echocardiography showing left ventricular ejection fraction (LVEF) ≥50% during screening, with an absolute decrease of ≤15% compared to pre-chemotherapy values; if no pre-chemotherapy LVEF assessment is available, LVEF must be ≥55% during screening; 8. Life expectancy ≥6 months; 9. For premenopausal or non-sterilized female patients: agreement to abstain from sexual activity or use effective non-hormonal contraception during study treatment and for 8 weeks after the last dose; 10. Willingness to participate voluntarily, provide signed informed consent, demonstrate good compliance, and cooperate with follow-up. Exclusion Criteria: 1. History of local or regional breast cancer recurrence; 2. Clinical stage IV (metastatic) breast cancer; 3. Bilateral breast cancer; 4. History of other malignant tumors within the past 5 years, except for curatively treated cervical carcinoma in situ, basal cell carcinoma, or cutaneous squamous cell carcinoma; 5. Prior treatment with pyrotinib, lapatinib, neratinib, or other tyrosine kinase inhibitors; trastuzumab emtansine; or any antitumor biological or immunotherapy; 6. Concurrent participation in another clinical trial involving antitumor therapy, including endocrine therapy, bisphosphonate therapy, or immunotherapy; 7. Significant cardiac disease, including: * Heart failure or systolic dysfunction (LVEF \< 50%); * Poorly controlled arrhythmias (e.g., atrial tachycardia, significant ventricular arrhythmia, or high-grade atrioventricular block); * Angina requiring antianginal medication; * Clinically significant valvular heart disease; * Electrocardiographic evidence of transmural myocardial infarction; * Poorly controlled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg) despite medication; 8. Impaired drug absorption due to dysphagia, intestinal obstruction, or other gastrointestinal disorders; 9. History of neurological or psychiatric conditions that may compromise compliance or informed consent; 10. Chronic gastrointestinal disorders with predominant diarrhea; 11. Known hypersensitivity to any study drug components; history of immunodeficiency (e.g., HIV positivity, congenital or acquired immunodeficiency disorder), or prior organ transplantation; 12. Pregnancy, lactation, or positive pregnancy test at baseline in women of childbearing potential; 13. Severe comorbidities that may interfere with treatment, including active infections (e.g., hepatitis B, hepatitis C, tuberculosis, syphilis) or any other condition deemed by the investigator to render the patient unsuitable for trial participation.
Conditions Wellness, Quality of Life, Anxiety, Depr...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study will examine the role of digital wellness modules (brief mindfulness and light to moderate physical exercise) delivered through a smartphone wellness application and their short-term effects on health behavior motivation and change, and longer-term quality of life and non-pathological affective states.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Device: Caravan Wellness app — Caravan Wellness is a digital platform that offers brief mindfulness and light to moderate physical activity modules, among many others (e.g., Pilates, Yoga, Barre, meditation, etc.), to enhance overall individual well-being.

Primary Outcomes

  • Change in Mindfulness assessed by the Five Facet Mindfulness Questionnaire (FFMQ) (baseline, 1 Month follow up, 3 Month follow up)
  • Change in Exercise Behavior assessed by the Behavior Regulation Exercise Questionnaire, Third Version (BREQ-3) (baseline, 1 Month follow up, 3 Month follow up)
  • Utility of the Modules assessed by self report (up to Day 22)
  • Daily stressors assessed using the Brief Daily Stressors Screening Tool (BDSST) (up to Day 22)
  • Average number of minutes spent on Intervention (up to Day 22)
  • Change in health behavior motivation assessed using the Health Behavior Motivation Scale (HBMS) (baseline, 1 Month follow up, 3 Month follow up)
  • CHange in health behavior assessed using he Health Behavior Inventory-20 (HBI-20). (baseline, 1 Month follow up, 3 Month follow up)
  • Quality of life assessed using the Quality of Life Inventory (QOLI) (baseline, 1 Month follow up, 3 Month follow up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-22
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: Caravan Wellness
Principal Investigators:
  • David Klemanski, Psy.D., MPH (PRINCIPAL_INVESTIGATOR) - Yale University
  • Margaret T Davis, MD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
David Klemanski, Psy.D., MPH
203.214.5426
david.klemanski@yale.edu
Margaret T Davis
margaret.t.davis@yale.edu
Interventions
  • Device: Caravan Wellness app — Caravan Wellness is a digital platform that offers brief mindfulness and light to moderate physical activity modules, among many others (e.g., Pilates, Yoga, Barre, meditation, etc.), to enhance overall individual well-being.
Study Locations (1 sites)
Yale University, New Haven, Connecticut 06520 United States
Eligibility Criteria
Inclusion Criteria: * Resides in United States Exclusion Criteria: * Any individual who endorses any of the following criteria will be excluded from participation in this study: * Positive Health Screening Questions, as measured by the Health Screening Questionnaire (HSQ): * Pain, discomfort or pressure in the chest, difficulty breathing or shortness of breath, dizziness, fainting, or blackout, blood pressure with systolic greater than 140 or diastolic greater than 90, diagnosed or treated for any heart disease, heart murmur, chest pain (angina), palpitations (irregular beat), or heart attack, heart surgery, angioplasty, or a pacemaker, valve replacement, or heart transplant, resting pulse greater than 100 beats per minute, any arthritis, back trouble, hip /knee/joint /pain, or any other bone or joint condition, personal experience or doctor's advice of any other medical or physical reason that would prohibit the participant from doing light to moderate physical exercise, personal physician's recommendation against participating in light to moderate physical exercise because of asthma, diabetes, epilepsy or elevated cholesterol or a hernia. * Positive Psychiatric Disorders Screening Questions: * Positive screen for depression, excluding suicide (PHQ-8) cutoff score \> 6 * Positive screen for panic (SMPD) cutoff score \> 2 * Positive screen for generalized anxiety (GAD-7) cutoff score \> 10 * Positive screen psychosis (PDSQ) via psychosis section, cutoff score \> 3 * Positive screen mania via the Altman Self-Rating Mania Scale (ASRM) cutoff score \> 6
Conditions Early Breast Cancer
Phase PHASE3
Enrollment 1400
Locations 229 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ribociclib — Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
  • Drug: Letrozole — Letrozole 2.5 mg orally once daily continuously
  • Drug: Ansastrozole — Anastrozole 1 mg orally once daily continuously.
  • Drug: Goserelin — Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
  • Drug: Leuprolide — Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
  • Drug: Exemestane — Exemestane 25 mg once daily continuously

Primary Outcomes

  • Invasive Breast Cancer Free Survival (iBCFS) rate at 3 years (At 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-02-28
Completion: 2030-09-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Principal Investigators:
  • Novartis Pharmaceuticals (STUDY_DIRECTOR) - Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
1-888-669-6682
novartis.email@novartis.com
Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com
Lorie Szymela
LSzymela@centralalabamaresearch.com
Central Alabama Research
Interventions
  • Drug: Ribociclib — Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
  • Drug: Letrozole — Letrozole 2.5 mg orally once daily continuously
  • Drug: Ansastrozole — Anastrozole 1 mg orally once daily continuously.
  • Drug: Goserelin — Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
  • Drug: Leuprolide — Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
Study Locations (229 sites)
Central Alabama Research, Birmingham, Alabama 35209 United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska 99508 United States
Western Reg MC-COH Phoenix, Goodyear, Arizona 85338 United States
CARTI Cancer Center, Little Rock, Arkansas 72205 United States
Beverly Hills Cancer Center, Beverly Hills, California 90211 United States
Onco Inst of Hope and Innovation, Cerritos, California 90703 United States
City of Hope National Medical, Duarte, California 91010 United States
Providence Medical Foundation, Fullerton, California 92835 United States
Los Angeles Cancer Network Good Samaritan, Los Angeles, California 90017 United States
El Camino Hospital, Mountain View, California 94040 United States
Eligibility Criteria
Key Inclusion criteria: * Participant is an adult, male or female ≥ 18 years of age at the time of informed consent form signature (IC). * Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer (BC) based on the most recently analyzed tissue sample tested by a local laboratory prior to enrollment. * Participant has HER2- BC defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing based on the most recently analyzed tissue sample. * Participants may have already received any standard neoadjuvant and/or adjuvant ET, including tamoxifen or toremifene at the time of informed consent signature, but enrollment should occur within 36 months of prior ET start date and participants should have at least 3 years remaining of endocrine adjuvant therapy. * For participants with prior ET treatment \> 12 months, restaging is highly recommended (unless contradictory to local regulations) to rule out disease recurrence prior to enrollment. * The number of participants with prior ET between 12 and 36 months will be capped at 30%. The cap will not apply to Black or African American participants. * Participant has no contraindication to receive adjuvant ET in the study. * Participant after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and belongs to one of the following categories: * Anatomic Stage Group III, or * Anatomic Stage Group IIB, or * A subset of Anatomic Stage Group IIA. * Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2. * Participant has adequate bone marrow and organ function. * ECG values assessed by KardiaMobile-6L device, or standard 12-lead ECG per local investigator where KardiaMobile-6L cannot be used, as: * QTcF interval at Screening \< 450 msec (QT interval using Fridericia's correction). * Mean resting heart rate 50-99 beats per minute (determined from the ECG). Key Exclusion criteria: * Participant with distant metastases of BC beyond regional lymph nodes (Stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery. * Participant is concurrently using other antineoplastic therapy with the exception of adjuvant ET. * Participant has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate participant participation in the clinical study or compromise compliance with the protocol, or limit life expectancy to ≤5 years. * Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality. * Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial. * Women of child-bearing potential (CBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 21 days after stopping the treatment. Other inclusion/exclusion criteria may apply
Conditions Asthma in Children
Phase Not Applicable
Enrollment 2
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To study the expression level of biomarkers such as GITRL in peripheral blood of children with asthma and analyze their correlation with the severity of asthma. To study the predictive value of biomarkers level for the occurrence and development of asthma. And to provide supplementary detection means and predictive indicators for the diagnosis of asthma and the severity of asthma.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: The level of biomarkers in Peripheral blood — All participants will be extracted 5ml peripheral blood into the anticoagulant tube by nurses and the peripheral blood will be detected for biomarkers of asthma. Children with asthma will take pulmonary function, blood test and specific IgE test etc. The lung function test will be performed by professional technicians and the results will be interpreted by specialists. The blood test and specific IgE test will be collected by specialist nurses and the results will be issued by professional inspectors. Children with asthma and their guardians will be asked for filling the questionnaire of Childhood Asthma Control Test (C-ACT). And then the doctor will check and calculate the scores after completion.

Primary Outcomes

  • The level of biomarkers (2years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-04
Completion: 2029-12-31
Eligibility
Age: 4 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital of Chongqing Medical University
Contact Information
Study Contact:
Ding Fengxia, PhD
86-15178712548
dingfengxia305@163.com
Li Yuehan, PhD student
86-15397618298
1214987864@qq.com
Yuehan Li, PHD student
15397618298
1214987864@qq.com
Shaoqing Zhang
Interventions
  • Diagnostic Test: The level of biomarkers in Peripheral blood — All participants will be extracted 5ml peripheral blood into the anticoagulant tube by nurses and the peripheral blood will be detected for biomarkers of asthma. Children with asthma will take pulmonary function, blood test and specific IgE test etc. The lung function test will be performed by professional technicians and the results will be interpreted by specialists. The blood test and specific IgE test will be collected by specialist nurses and the results will be issued by professional inspectors. Children with asthma and their guardians will be asked for filling the questionnaire of Childhood Asthma Control Test (C-ACT). And then the doctor will check and calculate the scores after completion.
Study Locations (1 sites)
Shaoqing Zhang, Chongqing, Chongqing Municipality 400000 China
Eligibility Criteria
Inclusion Criteria: * In line with the diagnostic criteria in the Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Children (2016 Edition) * Age: 4-12 years old for new diagnosis or recurrent episodes * Typical clinical manifestations and complete clinical data * Family members or guardians of children with informed research and signed consent * All healthy control subjects had no history of lung disease, allergic rhinitis or any other atopic disease Exclusion Criteria: * Suffering from other respiratory diseases (such as bronchiectasis, allergic rhinitis, respiratory failure, tuberculosis, obstructive airway disease) or other inflammatory diseases. * Abnormal development of congenital airway and lung tissue * History of immunosuppressant or glucocorticoid use in the first 4 weeks * Suffering from other endocrine system and immune system diseases * Incomplete clinical data or examinations.
Conditions Chronic Stress, Anxiety, Depression
Phase NA
Enrollment 360
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to the efficacy of the Building a Strong Identity and Coping Skills intervention within a sample of low-income and minoritized youth aged 11-14 who are seeking mental health treatment and have been placed on a waitlist to receive services. The aims of this study are to: (1) confirm the efficacy of BaSICS by replicating previous findings, (2) Examine the changes of coping mechanisms and symptom change over the course of the BaSICS intervention, and (3) test models of physiologic stress reactivity and regulation to capture biological "risk" and recalibration. Cohorts of 20 participants will randomly be enrolled in either the intervention (10) or control (10) groups. Participants enrolled in the intervention group will complete the BaSICS program and participants enrolled in the no intervention group will not be enrolled in the intervention program. The BaSICS program is designed to help treat anxiety, depression, and post-traumatic stress symptoms and disorders and have direct effects on physiologic stress response systems (hypothalamic-pituitary-adrenal (HPA) axis). Researchers will compare the intervention and no intervention groups to see if there is a difference in the reduction of markers for anxiety, depression, and suicide scores, changes in coping mechanism, and HPA reactivity profiles

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Building a Strong Identity and Coping Skills — Psychoeducational program to teach children coping skills, healthy identity development, and collective social action

Primary Outcomes

  • Anxiety (Pre-post (3 months) and Pre-follow up (6 and 12 months))
  • Depression (Pre-post (3 months) and Pre-follow up (6 and 12 months))
  • Suicide Risk Markers (Pre-post (3 months) and Pre-follow up (6 and 12 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-01
Completion: 2030-05-31
Eligibility
Age: 11 Years and older
Sex: ALL
Volunteers: true
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Penn State University
Principal Investigators:
  • Martha E Wadsworth, PhD (PRINCIPAL_INVESTIGATOR) - Penn State University
Contact Information
Study Contact:
Martha E Wadsworth, PhD
814-865-2878
mew27@psu.edu
Dara Babinksi, PhD
dbabinski@pennstatehealth.psu.edu
Jasmin Lagman, MD
jlagman@pennstatehealth.psu.edu
Pennsylvania Psychiatric Institute
Interventions
  • Behavioral: Building a Strong Identity and Coping Skills — Psychoeducational program to teach children coping skills, healthy identity development, and collective social action
Study Locations (5 sites)
Pennsylvania Psychiatric Institute, Harrisburg, Pennsylvania 17110 United States
Penn State Health Medical Group - Psychiatry and Behavioral Health, Hershey, Pennsylvania 17033 United States
Penns Valley Area School District, Spring Mills, Pennsylvania 16875 United States
Dr. Edwin L. Herr Clinic, State College, Pennsylvania 16802 United States
Penn State Psychological Clinic, State College, Pennsylvania 16802 United States
Eligibility Criteria
Inclusion Criteria: * Children ages 11-14 at intake * Family income at or below 200% federal poverty level * Child speaks English * Parent speaks English or Spanish Exclusion Criteria: * Intellectual disability * Autism spectrum disorder * High suicidal risk (score of 17 or more on the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid)) * Severe depression (score of 19 or more on Patient health questionnaire (PHQ).
Conditions Diabetes Mellitus Type 2 in Obese
Phase NA
Enrollment 286
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized controlled trial to determine whether a low-carbohydrate (LC) diet can lead to normalized blood glucose levels in patients with short duration of type 2 diabetes (T2D). Previous studies have shown that caloric restricted diet leading to weight loss can normalize blood glucose levels in approximately 50% of patients with a short duration of diabetes type 2. However, caloric restriction is difficult to maintain. Less restrictive approaches are needed. The hypothesis in this study is that Low carbohydrate diet can results in normalized blood glucose levels in T2D and can be an alternative to caloric restriction diet, both in the shorter term (3 months) and longer term (15 months). The outcome of this study leading to reduction of HbA1c is important for prevention of diabetes complications.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Low carb diet — Low calori diet

Primary Outcomes

  • non-diabetic HbA1c (After 3 months)
  • non diabetic HbA1c (After 15 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-02-28
Completion: 2027-02-28
Eligibility
Age: 24 Years and older
Sex: ALL
Volunteers: false
Enrollment: 286 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Stockholm
Principal Investigators:
  • Neda Rajamand Ekberg, MD, PhD (PRINCIPAL_INVESTIGATOR) - Region Stockholm
Contact Information
Study Contact:
Neda Rajamand Ekberg, M.D. PhD.
+468-123 671 50
neda.ekberg@ki.se
Katarina Fagerskiold, nurse
+468-123 671 76
katarina.fagerskiold@regionstockholm.se
Katarina Fagerskiold, nurse
+46-8-123 671 76.
katarina.fagerskiold@regionstockholm.se
Center for diabetes, Academic Specialist center
Interventions
  • Other: Low carb diet — Low calori diet
Study Locations (1 sites)
Center for diabetes, Academic Specialist center, Stockholm, Sweden
Eligibility Criteria
Inclusion Criteria: * HbA1c \> 48 mmol/mol (with or without medical treatment); * less than 6 years since the diagnosis of T2D * BMI ≥ 27 kg/m2 (≥ 25 kg/m2 for Asians). Exclusion Criteria: * Insulin deficiency. * HbA1c concentration of 12% or more (≥108 mmol/mol), * treatment with sulphonyl urea or sodium-glucose-cotrasporter2-inhibitor (SGL2-i), * myocardial infarction within the previous 6 months, * severe or unstable heart failure * other severe diseases including cancer, psychiatric/eating disorders, severe depression - substance abuse, * conditions that may affect the ability of patients to participate in the study
Conditions Breast Cancer, Hormone Receptor-positive...
Phase PHASE2
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The 3 FDA-approved CDK4, 6 inhibitors, palbociclib, ribociclib, and abemciclib, all provided progression-free survival benefits when combined with endocrine therapy in advanced ER+/HER2- breast cancer. But, not all of them provided overall survival benefit in the same setting. One of the proposed mechanisms that influence the overall survival difference is from the different influence of the 3 CDK4, 6 inhibitors on tumor microenvironment and/ or immune system. However, there was no head-to-head comparison of the 3 CDK4, 6 inhibitors in the same study. Neoadjuvant therapy provides a window to obtain tissue samples before treatment, during treatment, and after treatment. We aim to compare the immune modulation effects of palbociclib, ribociclib, and abemaciclib with letrozole in neoadjuvant treatment for ER+/HER2- early breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Palbociclib — CDK4, 6 inhibitor
  • Drug: Ribociclib — CDK4, 6 inhibitor
  • Drug: Abemaciclib — CDK4, 6 inhibitor
  • Drug: Letrozole — Endocrine therapy

Primary Outcomes

  • The expression of immune-related signature change after different CDK4/6 inhibitor treatments by RNAseq (Through study completion, an average of 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-09-16
Completion: 2026-09-30
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Principal Investigators:
  • Yen-Shen Lu, MD, PhD (PRINCIPAL_INVESTIGATOR) - National Taiwan University Hospital
Contact Information
Study Contact:
Yen-Shen Lu, MD, PhD
+886-2-23123456
yslu@ntu.edu.tw
Yen-Shen Lu, MD, PhD
886-2-23123456
yslu@ntu.edu.tw
Department of Oncology, National Taiwan University Hospital
Yen-Shen Lu, MD, PhD
Department of Oncology, National Taiwan University Hospital
Interventions
  • Drug: Palbociclib — CDK4, 6 inhibitor
  • Drug: Ribociclib — CDK4, 6 inhibitor
  • Drug: Abemaciclib — CDK4, 6 inhibitor
  • Drug: Letrozole — Endocrine therapy
Study Locations (2 sites)
Department of Oncology, National Taiwan University Hospital, Taipei, 100 Taiwan
Department of Oncology,National Taiwan University Hospital, Taipei, 100 Taiwan
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥ 20 years old at the time of informed consent. * Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory. with estrogen receptor positive (\>10%) on IHC staining and HER2 negative (IHC 0+/1+, or IHC 2+ plus FISH negative) * Stage II to III * With adequate organ function * ECOG 0-1 Exclusion Criteria: * Pregnant or nursing (lactating) women * Women of child-bearing potential unless using highly effective methods of contraception during study drug dosing and for 12 months post-dosing * Patients with active systemic infections or known to have AIDS or to test positive for HIV antibody at Screening * Any other disease or condition that could interfere with participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with the study procedures.
Conditions Platelet Aggregation, Type 2 Diabetes, A...
Phase PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase 2 study will include patients suffering from type 2 diabetes mellitus and will first study their response to enteric coated aspirin at a dose of 80 mg per day for a 7-day period. Participants with an incomplete platelet inhibition after exposure to EC aspirin at doses of 80 mg once daily will be randomized to a random order of 3 different ASA regimens: EC ASA 162 mg once daily, EC ASA 81 mg twice daily and chewable ASA 40 mg twice daily. The aims are to determine the feasibility of a larger scale trial, and to determine the regimen associated with the lowest proportion of non-responders after randomization. Platelet function will be assessed at baseline and at day 7 of each arms of the study.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Aspirin 81Mg Ec Tab twice daily for 7 days — Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
  • Drug: Aspirin 40Mg Chew Tab twice daily for 7 days — Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.
  • Drug: Aspirin 162 mg EC Tab once daily for 7 days — Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.

Primary Outcomes

  • Describe the screening rate to evaluate the feasibility of a larger scale randomized controlled trial. (1 year)
  • Describe the enrollment rate by the proportion of referred participants who are eligible to evaluate the feasibility of a larger scale randomized controlled trial. (1 year)
  • Describe the enrollment rate by the proportion of eligible participants who consent to evaluate the feasibility of a larger scale randomized controlled trial. (1 year)
  • Describe the retention rate to evaluate the feasibility of a larger scale randomized controlled trial. (1 year)
  • Among initial ASA non-responder participants, define the proportion of participants that remain ASA non-responders with different formulations and dosing regimens of ASA. (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-06-13
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Montreal Heart Institute
Collaborators: Heart and Stroke Foundation of Canada
Principal Investigators:
  • Guillaume Marquis Gravel, MD, MSc (PRINCIPAL_INVESTIGATOR) - ICM Co. Ltd.
Contact Information
Study Contact:
Guillaume Marquis Gravel, MD, MSc
514-376-3330
guillaume.marquis.gravel@umontreal.ca
Marie Lordkipanidzé B. Pharm, Ph.D.
514-376-3330
marie.lordkipanidze@umontreal.ca
Guillaume Marquis-Gravel, MD
Montreal Heart Institute
Interventions
  • Drug: Aspirin 81Mg Ec Tab twice daily for 7 days — Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
  • Drug: Aspirin 40Mg Chew Tab twice daily for 7 days — Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.
  • Drug: Aspirin 162 mg EC Tab once daily for 7 days — Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.
Study Locations (1 sites)
Montreal Heart Institute, Montreal, Quebec H1T 1C8 Canada
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. Participant must be naïve to ASA, defined as absence of chronic treatment with ASA within the previous 3 months, and of any ASA use within the previous 2 weeks; 3. Type 2 diabetes, based on at least one of the following criteria: (5) * Chronic treatment with oral antihyperglycemic agents or insulin therapy; * Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) (fasting is defined as no caloric intake for at least 8h); * 2-h Plasma Glucose (2h-PG) ≥ 200 mg/dL (11.1 mmol/L) during the oral glucose tolerance test (OGTT); * A1C ≥ 6.5% (48 mmol/ml); 4. Willing to attend all study visits of both the run-in and randomized phases of the trial. Exclusion Criteria: 1. Definitive indication for ASA, including any evidence of clinical atherosclerotic disease, previous or current; 2. Known hypersensitivity to ASA; 3. Patient requiring dialysis; 4. Severe hepatic insufficiency or ALT \> 3 x ULN; 5. High-risk GI bleeding features, such as known H. pylori infection, past or present ulcer, history of bleeding from the GI tract; 6. Bleeding diathesis; 7. Platelet count or hemoglobin levels outside of the normal reference range; 8. Planned major surgical procedure or dental procedure during the course of the study; 9. Chronic inflammatory disease requiring regular anti-inflammatory treatment; 10. Chronic treatment with an oral anticoagulant, an antiplatelet agent, NSAIDs or systemic steroids; 11. Active cancer; 12. History of hematological malignancy or myelodysplasia; 13. Pregnant or lactating women;